JNJ-42153605 | CAS#1254977-87-1 | PAM mGlu2

MedKoo Cat#: 526854 | Name: JNJ-42153605

Description:

WARNING: This product is for research use only, not for human or veterinary use.

JNJ-42153605 is a potent and selective mGlu2 receptor PAM with an acceptable pharmacokinetic profile in rodent and nonrodent species. JNJ-42153605 showed centrally mediated in vivo effectivity in models sensitive to mGlu2 receptor modulation such as sleep−wake electroencephalogram (sw-EEG) in rats,34 showing suppressed REM sleep during the first 4 h after oral administration of a 3 mg/kg dose.

Chemical Structure

JNJ-42153605

CAS#1254977-87-1

Theoretical Analysis

MedKoo Cat#: 526854

Name: JNJ-42153605

CAS#: 1254977-87-1

Chemical Formula: C22H23F3N4

Exact Mass: 400.1875

Molecular Weight: 400.45

Elemental Analysis: C, 65.99; H, 5.79; F, 14.23; N, 13.99

Price and Availability

Size	Price	Availability
25mg	USD 250.00	2 Weeks
50mg	USD 450.00	2 Weeks
100mg	USD 750.00	2 Weeks
200mg	USD 1,250.00	2 Weeks
500mg	USD 2,250.00	2 Weeks
1g	USD 3,250.00	2 Weeks
2g	USD 5,450.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

JNJ-42153605; JNJ 42153605; JNJ42153605.

IUPAC/Chemical Name

3-(Cyclopropylmethyl)-7-(4-phenyl-1-piperidinyl)-8-(trifluoromethyl)[1,2,4]triazolo[4,3-a]pyridine

InChi Key

BQAVZGJJQFJSMW-UHFFFAOYSA-N

InChi Code

InChI=1S/C22H23F3N4/c23-22(24,25)20-18(10-13-29-19(14-15-6-7-15)26-27-21(20)29)28-11-8-17(9-12-28)16-4-2-1-3-5-16/h1-5,10,13,15,17H,6-9,11-12,14H2

SMILES Code

FC(C1=C(N2CCC(C3=CC=CC=C3)CC2)C=CN4C1=NN=C4CC5CC5)(F)F

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

JNJ-42153605 is a positive allosteric modulator of the metabotropic glutamate 2 (mGlu2) receptor with an EC50 of 17 nM.

In vitro activity:

Consistent with the effects of an allosteric potentiator, JNJ-42153605 shifts the concentration-response curve of glutamate to the left (Fig 1C left panel), increasing the potency of glutamate up to ∼25-fold. At the human mGluR2, the EC50 of glutamate decreases from ∼10 to 0.5 μM with the addition of 3 μM JNJ-42153605. Reference: PLoS One. 2015 Dec 11;10(12):e0144017. https://pubmed.ncbi.nlm.nih.gov/26658273/

In vivo activity:

JNJ-40411813, JNJ-42153605, and LY404039 dose dependently inhibited spontaneous locomotion and PCP- and scopolamine-induced hyperlocomotion but not d-amphetamine-induced hyperlocomotion (Fig. 2; Table 2) in mice. Reference: Pharmacol Res Perspect. 2015 Mar;3(2):e00097. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4324682/

	Solvent	mg/mL	mM
Solubility
	DMF	30.0	74.92
	DMF:PBS (pH 7.2) (1:3)	0.3	0.62
	DMSO	10.3	25.81
	Ethanol	10.0	24.97

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 400.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Ahnaou A, Lavreysen H, Tresadern G, Cid JM, Drinkenburg WH. mGlu2 Receptor Agonism, but Not Positive Allosteric Modulation, Elicits Rapid Tolerance towards Their Primary Efficacy on Sleep Measures in Rats. PLoS One. 2015 Dec 11;10(12):e0144017. doi: 10.1371/journal.pone.0144017. PMID: 26658273; PMCID: PMC4684355. 2. Lavreysen H, Langlois X, Donck LV, Nuñez JM, Pype S, Lütjens R, Megens A. Preclinical evaluation of the antipsychotic potential of the mGlu2-positive allosteric modulator JNJ-40411813. Pharmacol Res Perspect. 2015 Mar;3(2):e00097. doi: 10.1002/prp2.97. Epub 2015 Jan 30. PMID: 25692027; PMCID: PMC4324682. 3. Cid JM, Tresadern G, Vega JA, de Lucas AI, Matesanz E, Iturrino L, Linares ML, Garcia A, Andrés JI, Macdonald GJ, Oehlrich D, Lavreysen H, Megens A, Ahnaou A, Drinkenburg W, Mackie C, Pype S, Gallacher D, Trabanco AA. Discovery of 3-cyclopropylmethyl-7-(4-phenylpiperidin-1-yl)-8-trifluoromethyl[1,2,4]triazolo[4,3-a]pyridine (JNJ-42153605): a positive allosteric modulator of the metabotropic glutamate 2 receptor. J Med Chem. 2012 Oct 25;55(20):8770-89. doi: 10.1021/jm3010724. Epub 2012 Oct 16. PMID: 23072213.

In vitro protocol:

In vivo protocol:

1. Lavreysen H, Langlois X, Donck LV, Nuñez JM, Pype S, Lütjens R, Megens A. Preclinical evaluation of the antipsychotic potential of the mGlu2-positive allosteric modulator JNJ-40411813. Pharmacol Res Perspect. 2015 Mar;3(2):e00097. doi: 10.1002/prp2.97. Epub 2015 Jan 30. PMID: 25692027; PMCID: PMC4324682. 2. Cid JM, Tresadern G, Vega JA, de Lucas AI, Matesanz E, Iturrino L, Linares ML, Garcia A, Andrés JI, Macdonald GJ, Oehlrich D, Lavreysen H, Megens A, Ahnaou A, Drinkenburg W, Mackie C, Pype S, Gallacher D, Trabanco AA. Discovery of 3-cyclopropylmethyl-7-(4-phenylpiperidin-1-yl)-8-trifluoromethyl[1,2,4]triazolo[4,3-a]pyridine (JNJ-42153605): a positive allosteric modulator of the metabotropic glutamate 2 receptor. J Med Chem. 2012 Oct 25;55(20):8770-89. doi: 10.1021/jm3010724. Epub 2012 Oct 16. PMID: 23072213.

1: Ahnaou A, Lavreysen H, Tresadern G, Cid JM, Drinkenburg WH. mGlu2 Receptor Agonism, but Not Positive Allosteric Modulation, Elicits Rapid Tolerance towards Their Primary Efficacy on Sleep Measures in Rats. PLoS One. 2015 Dec 11;10(12):e0144017. doi: 10.1371/journal.pone.0144017. eCollection 2015. PubMed PMID: 26658273; PubMed Central PMCID: PMC4684355. 2: Lavreysen H, Langlois X, Donck LV, Nuñez JM, Pype S, Lütjens R, Megens A. Preclinical evaluation of the antipsychotic potential of the mGlu2-positive allosteric modulator JNJ-40411813. Pharmacol Res Perspect. 2015 Mar;3(2):e00097. doi: 10.1002/prp2.97. Epub 2015 Jan 30. PubMed PMID: 25692027; PubMed Central PMCID: PMC4324682. 3: Wyckhuys T, Wyffels L, Langlois X, Schmidt M, Stroobants S, Staelens S. The [18F]FDG μPET readout of a brain activation model to evaluate the metabotropic glutamate receptor 2 positive allosteric modulator JNJ-42153605. J Pharmacol Exp Ther. 2014 Aug;350(2):375-86. doi: 10.1124/jpet.114.213959. Epub 2014 Jun 4. PubMed PMID: 24898267. 4: Megens AA, Hendrickx HM, Hens KA, Talloen WJ, Lavreysen H. mGlu(2) receptor-mediated modulation of conditioned avoidance behavior in rats. Eur J Pharmacol. 2014 Mar 15;727:130-9. doi: 10.1016/j.ejphar.2014.01.044. Epub 2014 Jan 30. PubMed PMID: 24486391. 5: Cid JM, Tresadern G, Vega JA, de Lucas AI, Matesanz E, Iturrino L, Linares ML, Garcia A, Andrés JI, Macdonald GJ, Oehlrich D, Lavreysen H, Megens A, Ahnaou A, Drinkenburg W, Mackie C, Pype S, Gallacher D, Trabanco AA. Discovery of 3-cyclopropylmethyl-7-(4-phenylpiperidin-1-yl)-8-trifluoromethyl[1,2,4]triazolo[4 ,3-a]pyridine (JNJ-42153605): a positive allosteric modulator of the metabotropic glutamate 2 receptor. J Med Chem. 2012 Oct 25;55(20):8770-89. doi: 10.1021/jm3010724. Epub 2012 Oct 16. PubMed PMID: 23072213.